Physician profile
Paul Spiro
NPI 1578548939
$2,037.24
in general payments reported to CMS, 2019-2025
28 companies · $202 in 2025
The $202 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $414 · 2020: $147 · 2022: $349 · 2023: $412 · 2024: $513 · 2025: $202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,126.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $346.62 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $241.00 | 2019-2025 | |
| Daiichi Sankyo INC. | $232.77 | 2019-2025 | Injectafer |
| Merck Sharp & Dohme LLC | $134.69 | 2019-2024 | Capvaxive, Gardasil 9, Gardasil |
| Glaxosmithkline, LLC. | $127.42 | 2019-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Exact Sciences Corporation | $117.95 | 2023-2024 | Cologuard Collection Kit |
| Lilly USA, LLC | $85.75 | 2020-2025 | Mounjaro, Zepbound |
| Bausch Health US, LLC | $80.38 | 2019-2025 | Wellbutrin |
| Astrazeneca Pharmaceuticals LP | $73.78 | 2019-2020 | |
| Sanofi Pasteur INC. | $71.42 | 2019-2025 | |
| Abbvie INC. | $51.68 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $49.47 | 2019-2023 | |
| Dynavax Technologies Corporation | $44.08 | 2022-2023 | Heplisav-B |
| Janssen Pharmaceuticals, INC | $42.20 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $41.61 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Modernatx, INC. | $35.91 | 2024 | Moderna Covid-19 Vaccine |
| Bayer Healthcare Pharmaceuticals INC. | $32.72 | 2022-2023 | |
| Xeris Pharmaceuticals, INC. | $32.29 | 2022-2024 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.77 | 2023 | |
| Alexion Pharmaceuticals, INC. | $24.98 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.81 | 2025 | Xifaxan |
| Inspire Medical Systems, INC. | $23.70 | 2024 | Inspire |
| Sanofi-Aventis U.S. LLC | $21.22 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $16.82 | 2024 | Camzyos |
| Phathom Pharmaceuticals, INC. | $15.76 | 2024 | Voquezna |
| Astellas Pharma US INC | $14.98 | 2020 | |
| Collegium Pharmaceutical, INC. | $12.81 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Spiro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.